EXENDUBEK Trademark

Trademark Overview


On Friday, May 17, 2024, a trademark application was filed for EXENDUBEK with the United States Patent and Trademark Office. The USPTO has given the EXENDUBEK trademark a serial number of 98555936. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, November 22, 2024. This trademark is owned by Celgene Corporation. The EXENDUBEK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for human use.

General Information


Serial Number98555936
Word MarkEXENDUBEK
Filing DateFriday, May 17, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, November 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for human use.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 17, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Friday, May 17, 2024NEW APPLICATION ENTERED
Wednesday, November 20, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 21, 2024ASSIGNED TO EXAMINER
Friday, November 22, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 22, 2024NON-FINAL ACTION WRITTEN
Friday, November 22, 2024NON-FINAL ACTION E-MAILED